Skip to content
Markets News
Stocks1 min read

CG Oncology Reports 68% Lower Recurrence Risk in Phase 3 Trial

Makkler Newsroom
November 16, 2026 · Based on reporting by GlobeNewswire

CG Oncology reported a 68% lower recurrence risk in a Phase 3 trial and outlined plans for two bladder-cancer submissions.

Key takeaways

  • PIVOT-006 showed a 68% reduction in recurrence risk versus the control arm.
  • CG Oncology expects a second BLA submission in the second quarter of 2027.

CG Oncology said its Phase 3 PIVOT-006 trial met its primary endpoint, with cretostimogene reducing the risk of recurrence by 68% versus the control arm. The company reported a hazard ratio of 0.32 and said the topline results were based on a median follow-up of 17 months.

The company said there were no treatment-related adverse events of Grade 3 or higher and no treatment-related discontinuations. The candidate is investigational, and its safety and efficacy have not been established by the FDA.

CG Oncology plans to complete its initial BLA submission for BCG-unresponsive disease by the end of March 2027, broadened to include high-grade papillary-only disease. It expects a second submission for intermediate-risk and high-grade Ta disease in the second quarter of 2027.

Topics

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.